Vascular Calcification - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Vascular Calcification – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Vascular Calcification pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vascular Calcification: Overview
Vascular calcifications are deposits of mineral on the walls of arteries, veins, and even heart valves. These deposits at times stick to the fatty deposits or plaques which are already present on the blood vessel wall. Vascular calcifications increase the risk of inadequate blood supply to extremities, renal insufficiency, dementia, stroke, and heart attack.
“Vascular Calcification - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Calcification pipeline landscape is provided which includes the disease overview and Vascular Calcification treatment guidelines. The assessment part of the report embraces, in depth Vascular Calcification commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Calcification collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Calcification R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Calcification.
Vascular Calcification Emerging Drugs Chapters
This segment of the Vascular Calcification report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Calcification Emerging Drugs
SN472: Sanifit
Sanifit’s drug molecule SN472 is a novel small molecule, and a potent and selective inhibitor of hydroxyapatite crystallization that is the common pathway leading to vascular calcification. It is in different stages of drug development according to the targeted conditions in which vascular calcification takes place.
Further product details are provided in the report……..
Vascular Calcification: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Calcification drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Vascular Calcification
There are approx. 3+ key companies which are developing the therapies for Vascular Calcification. The companies which have their Vascular Calcification drug candidates in the mid to advanced stage, i.e. phase III include, Sanifit and others.
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
Vascular Calcification pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Vascular Calcification: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Calcification therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Calcification drugs.
Vascular Calcification Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Vascular Calcification – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Vascular Calcification pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vascular Calcification: Overview
Vascular calcifications are deposits of mineral on the walls of arteries, veins, and even heart valves. These deposits at times stick to the fatty deposits or plaques which are already present on the blood vessel wall. Vascular calcifications increase the risk of inadequate blood supply to extremities, renal insufficiency, dementia, stroke, and heart attack.
“Vascular Calcification - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Calcification pipeline landscape is provided which includes the disease overview and Vascular Calcification treatment guidelines. The assessment part of the report embraces, in depth Vascular Calcification commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Calcification collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Calcification R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Calcification.
Vascular Calcification Emerging Drugs Chapters
This segment of the Vascular Calcification report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Calcification Emerging Drugs
SN472: Sanifit
Sanifit’s drug molecule SN472 is a novel small molecule, and a potent and selective inhibitor of hydroxyapatite crystallization that is the common pathway leading to vascular calcification. It is in different stages of drug development according to the targeted conditions in which vascular calcification takes place.
Further product details are provided in the report……..
Vascular Calcification: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Calcification drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Vascular Calcification
There are approx. 3+ key companies which are developing the therapies for Vascular Calcification. The companies which have their Vascular Calcification drug candidates in the mid to advanced stage, i.e. phase III include, Sanifit and others.
Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Vascular Calcification pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Vascular Calcification: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Calcification therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Calcification drugs.
Vascular Calcification Report Insights
- Vascular Calcification Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vascular Calcification drugs?
- How many Vascular Calcification drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Calcification?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Calcification therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vascular Calcification and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sanifit
- Inositec
- SN 472
- INS-3001
Introduction
Executive Summary
Vascular Calcification: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vascular Calcification – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vascular Calcification companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vascular Calcification Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SN 472: Sanifit
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular Calcification Key Companies
Vascular Calcification Key Products
Vascular Calcification- Unmet Needs
Vascular Calcification- Market Drivers and Barriers
Vascular Calcification- Future Perspectives and Conclusion
Vascular Calcification Analyst Views
Vascular Calcification Key Companies
Appendix
Executive Summary
Vascular Calcification: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vascular Calcification – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vascular Calcification companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vascular Calcification Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SN 472: Sanifit
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular Calcification Key Companies
Vascular Calcification Key Products
Vascular Calcification- Unmet Needs
Vascular Calcification- Market Drivers and Barriers
Vascular Calcification- Future Perspectives and Conclusion
Vascular Calcification Analyst Views
Vascular Calcification Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Vascular Calcification
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Vascular Calcification
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Vascular Calcification
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Vascular Calcification
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
